Tags: Cancer | xgeva | bone | tumor | gctb

New Medication Fights Bone Tumors

Friday, 14 Jun 2013 03:23 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

The tumor usually affects adults between ages 20 and 40, although it may also develop in adolescents, the FDA said. It typically doesn't spread, although in rare cases it can become cancerous and travel to the lungs.
 
As a non-cancerous tumor, GCTB destroys bone as it becomes larger, causing pain, fractures, and loss of mobility. Xgeva has been approved in cases where the tumor can't be surgically removed, or might lead to a severe outcome such as loss of a limb, the agency said.
 
Xgeva, approved under the FDA's expedited review program, was evaluated for this use in two clinical trials involving a total of 305 adults and adolescents. Common side effects included joint pain, headache, nausea, fatigue, back pain, and extremity pain.
 
Women of childbearing potential should use "highly effective" contraception while taking Xgeva, since the drug can harm a fetus, the FDA warned.
 
The drug was first approved in 2010 to prevent fractures when cancer has spread to the bone. It's marketed by Amgen, based in Thousand Oaks, Calif.

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

New Painkiller Discourages Abuse

Thursday, 24 Jul 2014 16:38 PM

A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the dr . . .

Zydelig Treats Three Types of Blood Cancer

Wednesday, 23 Jul 2014 17:02 PM

The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat t . . .

Help for Hereditary Angioedema

Friday, 18 Jul 2014 08:36 AM

Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease th . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved